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The clinical pathologic syndrome ofgraft-versus-host disease (GVHD) is usually a sequela of
bone marrow transplantation. This disorder occurs as a result of recognition by engrafted
donor-derived lymphocytes of "foreign" recipient transplantation antigens. GVHD may also
result from engraftment oflymphocytes from other sources, including (1) transfusion oflympho-
cytes containing blood components, (2) transplacental maternal fetal transfusion, and (3) passive
transfer of lymphocytes in solid organ transplantation. The recipients are usually severely
immunodeficient andthus incapableofrejecting thetransfused lymphocytes. Thissyndrome may,
however, also develop in immunologically competent patients receiving blood products from
individuals with histocompatibility antigens not recognized as foreign.
GRAFT-VERSUS-HOST DISEASE: CLINICAL SYNDROME
Graft-versus-host disease (GVHD) is a clinico-pathologic process which develops
predominantly in the setting of bone marrow transplantation. It is, in fact, the major
rate-limiting step in the utilization of marrow grafting for the treatment of a host of
human diseases, often presenting with life-threatening complications even in recipients
ofhistocompatible transplants. An extremely high incidence ofsevere GVHD is noted
in the setting of bone marrow transplants from non-histocompatible marrow donors.
Thus, the absenceofan appropriate HLA-(histocompatible locus antigen) compatible,
MLC (mixed lymphocyte culture) non-reactive donor may prevent the use of this
therapeutic modality in patients for whom it represents pathophysiologically rational
treatment. A variety of pharmacologic and biologic therapies have been tried for the
purpose of ameliorating or eliminating this condition. Based on the fact that T cells
appear at least to initiate this condition, ex vivo depletion of T lymphocytes from the
bone marrow has been attempted to overcome these barriers.
Clinically, graft-versus-host disease in the setting of marrow transplantation may
manifest itself as two distinct syndromes. The first is an acute syndrome, appearing
from seven to 50 days post-transplant, and is associated predominantly with a skin
eruption, hepatitis, and gastrointestinal dysfunction [1]. The dermatologic manifesta-
tions may vary from a mild diffuse erythematous rash to a severe epidermal necrolysis
syndrome. The hepatic syndrome is predominantly reflected by hepatocellular enzyme
and bilirubin abnormalities, and the gastrointestinal dysfunction is associated with
nausea, vomiting, and diarrhea. Characteristic pathologic findings are noted, particu-
larly in the skin [2,3]. Acute GVHD may occur in 40-80 percent of patients who
receive histocompatible transplants, with a severe syndrome developing in 30 to 50
percent ofrecipients despite treatment with a variety ofGVHD prophylaxis regimens
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[4-6]. Treatment of moderate to severe acute GVHD includes the use of high-dose
pulse corticosteroids, antithymocyte serum, cyclosporine, and a variety of monoclonal
antibody preparations. These therapeutic modalities result in resolution of the acute
syndrome in approximately 50 percent of patients [7]. The second syndrome, chronic
GVHD, may develop from two months to one year post-transplant and has distinctive
clinical and pathological manifestations [8]. This reaction also predominantly affects
the skin, liver, and gastrointestinal tract and has many of the characteristics of
scleroderma. Bone marrow transplant recipients with histocompatible donors may
develop one or both ofthese reactions.
From a pathophysiological point of view, graft-versus-host disease results from
engrafted donor lymphocytes which recognize a foreign antigen in the recipient [9]. In
the case of histocompatible donors, the lymphoid cells presumably recognize a minor
non-HLA antigen. Extensive animal studies have demonstrated that the more dispa-
rate the donor and recipient, the more frequent and severe the reaction [10]. Second,
although the pathophysiology of the entire cascade of events in the graft-versus-host
disease reaction is unclear, the event is initiated by a T lymphocyte. The severity ofthe
reaction has been demonstrated in part to be dependent upon the number of T
lymphocytes contaminating the bone marrow infusion [10]. Thus, both the degree of
disparity and the number of engrafted lymphocytes influence the incidence and
severity of the GVHD reaction. Of interest is the fact that an acute GVHD-like
syndrome has been noted in some recipients ofsyngeneic (identical twin) or autologous
(self) transplants, in which neither major histocompatibility nor presumptive minor
histocompatibility antigenic differences would be expected [11]. This observation
suggests that other processes, possibly of an "autoimmune" nature, result in this
reaction in some situations.
TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE
Although graft-versus-host disease is primarily associated with bone marrow trans-
plantation, this reaction has alsobeen noted on occasion in othersettings. In particular,
GVHD has resulted from blood transfusions with a variety ofproducts, transplacental
transfusions, or passive administration of lymphocytes in solid organ transplants.
Again, the requirements for GVHD in thesesettings include: (1) engraftment ofviable
donor T lymphocytes capable of further cell division, (2) the recognition of foreign
transplantation antigens by the donor lymphocytes, and (3) failure of the host recipi-
ent's immune system to eliminate or reject the donor T cells. This last requirement is
what prevents routine blood transfusion from establishing GVHD in recipients more
frequently. The majority of transfusion recipients are sufficiently immunocompetent,
in particular have an adequate T-cell response, to reject the donor T lymphocytes
before the latter can establish GVHD.
Theoverall risk oftransfusion-associated GVHD is unknown and is probably higher
than the approximately 60-70 cases reported in the literature [12,13]. In fact, many
tertiary institutions, where patients at high risk are routinely treated, establish a
diagnosis of transfusion-associated GVHD approximately once a year. Transfusion-
associated GVHD is probably often unrecognized in the setting of complex medical
situations, where target organs are already dysfunctional. Furthermore, incomplete
manifestations of the triad of GVHD may be present, or the syndrome may be mild.
Finally, the potential diagnosis may be missed and not associated with a transfusion
administered up to a month previously.
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Since transfusion-associated GVHD is preventable, the question of who is at risk
must be addressed. Clearly the cases presented in the literature establish certain
high-risk populations ofpatients. These groups includechildren with the relatively rare
genetic immunodeficiency states, including severe combined immunodeficiency,
DiGeorge syndrome, and the Wiskott-Aldrich syndrome [14-17]. Since the T-cell
compartment is usually intact in either the acquired or congenital hypogammaglobu-
linemias, GVHD has not been reported in this setting. A second group at high risk are
neonates, particularly those who have received either intrauterine or postnatal ex-
change transfusions [18]. In this setting, the immune system of the newborn may be
insufficiently mature to rejecttransfused foreign Tcells. Furthermore, massivetransfu-
sions may result in either immunological tolerance or further immune suppression
[19]. Finally, a group at high risk for GVHD are all allogeneic or autologous bone
marrow transplant recipients. This risk results from the chemoradiation preparative
regimens, which render the patient totally immunodeficient, as well as the prolonged
immunologic recapitulation post-transplant [20,21]. Patients aretreated as susceptible
to transfusional GVHD for their entire lives, although this susceptibility has never
actually been tested. The incidence of reported transfusion-associated GVHD post-
marrow grafting is low, because it has long been established practice to administeronly
irradiated blood products to these patients. Furthermore the situation is further
confused by the fact that thedevelopment ofGVHD is most commonly associated with
the donor lymphocytes in the transplant. In one series of autologous bone marrow
transplants, however, four of 25 patients receiving unirradiated blood products devel-
oped fatal GVHD [22].
Groups at lower, but some, risk include patients receiving chemoradiation therapy
for malignancies, which results in marked immunosuppression. Thirty cases have been
reported, predominantly in patients with hematologic malignancies, including 11
patients with Hodgkin'sdisease, fivepatients with non-Hodgkin's lymphoma, ninewith
acute non-lymphocytic leukemia, and five with acute lymphoblastic leukemia [12,13].
Only four cases have been reported in association with treatment for solid tumors
[23-26]. The risk ofpost-transfusion-associated GVHD in this setting is very difficult
to establish and is clearlyvariable, depending upon the treatment regimen. In addition,
mild cases are probably underdiagnosed in this setting, and the incidence is probably
higher than reported. Given the few cases reported in these more common disorders,
however, a definite but lower risk must be assumed. Of note is that over two-thirds of
the patients had malignancies of the lymphoid system. Perhaps a disease-associated
immune defect exists and/or the therapy for these diseases is more immunosuppres-
sive. In most cases in which transfusion-associated GVHD is noted, the patients have
received extraordinarily intensive therapy, and GVHD occurs during the period of
intense immunosuppression.
Of note is the fact that to date no cases oftransfusion-associated GVHD have been
reported in patients with the acquired immunodeficiency state, despite a profound
T-cell defect as well as frequent transfusion therapy. Perhaps transfused lymphocytes
are immunologically immobilized by the same retroviral infection. Similarly, only a
rare case of GVHD has been noted in recipients of solid organ transplants, despite
massive transfusions and prolonged and intense immunosuppression [27,28]. The
GVHD which occurs in this setting could result from either blood transfusions or
passive transfer of lymphocytes in the donor organ. The author has noted prolonged
engraftment ofPhiladelphia chromosome positive donor cells for six months in a renal
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transplant recipient who received an unirradiated granulocyte transfusion from a
patient with chronic myelogenous leukemia [unpublished observation]. In at least
two-thirds of patients with acquired aplastic anemia, an intact immune system can be
demonstrated, and thus only one case of transfusional GVHD has been observed in a
patient with severe aplastic anemia [29]. Theoretically patients with severe aplastic
anemiaundergoingimmunosuppressivetherapywithantithymocyteglobulin,cyclospo-
rine, or high-dose corticosteroids should be at risk for transfusion-associated GVHD,
but no cases have yet been reported, despite the fact that these patients do not
consistently receive irradiated blood. Perhaps in this setting the multiplicity of
transfusions results in a graft-versus-graft reaction, with destruction of potential
lymphoid engraftment ofany given donor.
POST-OPERATIVE ERYTHRODERMA
In the mid 1950s, several cases of post-operative erythroderma were reported in
presumably immunologically normal Japanese recipients of blood transfusions [30].
Most ofthese transfusions were relatively fresh units ofwhole blood donated by family
members. Only years later was thefactrecognized thatthisreaction did not represent a
drug allergy, but was post-transfusion graft-versus-host disease. A number ofcases, 90
from Japan, have been documented more recently in immunologically normal individ-
uals [31]. The issue became clearer with the report from Israel of two cases of fatal
post-cardiac surgery transfusion-associated GVHD [32]. In both cases, unirradiated
blood transfusions from children ofthe patients were administered. HLA typing ofthe
respective donors demonstrated that the donors were HLA-homozygous and thus did
not have HLA-A or HLA-B antigens that were foreign to the recipient. This circum-
stance, in which fresh blood with large numbers of viable lymphocytes was adminis-
tered, allowed engraftment of immunocompetent donor lymphocytes, which then
recognized the recipient as foreign, provoking a subsequent GVHD reaction. In one
Japanese case, similar findings were noted [33]. The Japanese have recently reported
an incidence offatal transfusion-associated GVHD in 0.2 percent ofpatients undergo-
ing cardiac surgery [34]. This reaction may in part be due to the use oflarge amounts
of relatively fresh blood but has probably been largely noted in Japan because of the
practice of utilizing family members as blood donors, as well as the fact that a
relatively limited HLA gene pool exists in this genetically homogeneous population.
Clearly, as blood transfusion practices change in response to fears of transfusion-
transmitted infections, caution will have tobe exercised in the useofdirected donations
from family members. Certainly fresh blood products should be avoided, ifpossible.
NON-TRANSFUSION, NON-BONE MARROW TRANSPLANT GVHD
Other sources ofnon-bone marrow transplantation GVHD have also been reported.
Clearly, passive transfer of lymphocytes in solid organ transplants into immunosup-
pressed recipients is a possible cause [27,28]. Relatively small numbers oflymphocytes
are present in the vasculature of the kidney, heart, liver, and lung, and the number is
probably further diminished by flushing with the organ preservatives; however, large
numbersoflymphocytes aretransplanted inrecipientsofspleen,pancreas, orgastrointes-
tinal transplants. In order to prevent GVHD, low-dose irradiation isoften administered
to these organs ex vivo. Another documented source of GVHD is the transplacental
transfer of maternal T cells to fetuses with severe combined innumodefiency, with
subsequent engraftment. In three cases, GVHD was ascribed to this phenomenon by
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typing of the lymphocytes [35-37]. A subsequent sequential study in these children
demonstrated, however, that, despite a 25 percent incidence of engraftment, the
maternal-fetal GVHD syndrome was rarely observed [38]. In vitro functional studies
ofthe transplanted maternal lymphocytes demonstrated that they were immunoincom-
petent.
LYMPHOCYTE SOURCES
The risk of graft-versus-host disease has been demonstrated to be dependent upon
the dose of administered lymphocytes in both mice and humans. As few as 107
lymphocytes/kg or perhaps less can cause fatal GVHD; hence sufficient lymphocytes
can be transfused from a single unit of blood, which contains from 1 to 2 x 109
lymphocytes [39]. Viable lymphocytes have been detected in two- to three-week-old
blood, although most reported cases have resulted from relatively fresh packed cells or
whole blood. GVHD has also been observed following the transfusion of buffy coats,
platelets, and granulocytes, indicating that sufficient lymphocytes exist in these
preparations to induce the reaction. Fresh plasma, with relatively fewer lymphocytes
(1.5 x 105 lymphocytes) has only been implicated as the source of transfusion-
associated GVHD in small children with congenital severe immunodeficiencies [40].
No reports have implicated fresh frozen plasma or cryoprecipitate. The lower limit of
requisite numbers oflymphocytes is unclear; however, the dose dependency may make
children more susceptible than larger adults.
CLINICAL SYNDROME, DIAGNOSIS, AND TREATMENT OF
TRANSFUSION-ASSOCIATED GVHD
The clinical syndrome is similar in many respects to that associated with post-bone
marrow transplant GVHD. Fever is commonly the presenting symptom, occurring four
to 30 days, with a median ofeight days, following the transfusion. A skin rash develops
either simultaneously or shortly thereafter and may vary in intensity from diffuse
erythema to a maculopapular eruption to a toxic epidermal lysis picture. Liver
dysfunction is primarily hepatocellular, and the syndrome is often accompanied by
watery diarrhea. All three organs have characteristic histological manifestations
described extensively elsewhere [1]. A unique aspect of post-transfusion GVHD is an
associated pancytopenia with bone marrow aplasia in 66 percent of patients [41]. This
distinguishing aspect differs from bone marrow transplant GVHD since, in the latter
situation, both the lymphoid system and hematopoietic cells are derived from the
donor. One case has been reported in which transfusion GVHD resulted in rejection of
a bone marrow graft [42]. Unlike bone marrow transplant-related GVHD, the
majority of reported cases following transfusion have been fatal, with infection as the
primary cause ofdeath. The poorer survival may be due to the greater genetic disparity
encountered in the post-transfusion state. A somewhat better survival has been noted in
patients treated for acute non-lymphocytic leukemia. Only rarely has chronic graft-
versus-host disease been reported post-transfusion [43].
The diagnosis of GVHD is usually established by the clinical features as well as
classic histopathology. A number ofviral infections, particularly cytomegalovirus, can
mimic this syndrome and are common in similar clinical scenarios. Reactions to a
variety of drugs, including chemotherapy and antibiotics, must also be considered.
Irradiation therapy can also cause similar findings. Of interest is the development of
autologous or syngeneic graft-versus-host disease with reconstitution ofan unbalanced
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immune system [11]. A rat model has demostrated a cyclosporine-associated GVHD
reaction [44]. Thus, autologous GVHD must be considered, but this reaction is usually
a mild syndrome. The diagnosis of transfusion-associated GVHD can be strongly
supported by evidence of lymphoid engraftment. This process can be demonstrated
through cytogenetic studies and/or through HLA typing oflymphocytes. Both ofthese
studies can be difficult because of the usual lymphopenia. HLA typing may demon-
strate a number of findings, including the identification of more than two HLA
haplotypes or, in the case of homozygous donors, only a single haplotype. Family
studies may need to be done to confirm the patient's genotype. Retrospective HLA
typing ofthe blood donors can confirm the sourceofthe GVHD.
Treatment of post-transfusion GVHD has in general been unsuccessful. Patients
have been treated with high-dose corticosteroids, antithymocyte globulin, monoclonal
antibodies, and cyclosporine. Despite therapy, mortality rates of 80-90 percent have
been noted, with the best survival in patients being treated for acute non-lymphocytic
leukemia. Presumably, in the latter situation, ultimate recovery of the patient's own
immune system results in rejection ofthe engrafted lymphocytes. A better survival has
also been noted in recipients of granulocytes from donors with chronic myelogenous
leukemia [45].
PREVENTION
Since treatment of transfusion-associated GVHD has been unsuccessful, the main
effort should be prophylaxis. Techniques to remove leukocytes physically from blood
products may reduce the number of viable lymphocytes by 1 to 3 logs but will not
entirely eliminate the putative effector cells [46,47]. These techniques include washing
or freezing red cells in glycerol or DMSO, or filtration of platelets. As many as 106
lymphocytes, perhaps a number adequate to produce GVHD in severely immunosup-
pressed children, may be found in a filtered transfusion.
At the present time, prophylactic ex vivo irradiation of blood products prior to
transfusions is the most efficient and standard method for GVHD prevention. In most
centers, irradiation is administered in a few minutes, with relatively cheap and
compact cesium 137 sources with a rotating chamber adequate to hold a unit ofblood.
Blood bank technologists can quickly master the technique. Attention does need to be
paid to quality control. For centers with less frequent needs for irradiated blood
products, conventional X-ray therapy equipment can be utilized, but this method is a
cumbersome process, requiring a number of individuals. Although the current doses
administered are usually between 1,500 and 3,000 rads, debate still exists about the
appropriate dose. Clearly, doses of 1,500 rads will decrease the response of lympho-
cytes to mitogens by 85 percent and will prevent a response in a mixed lymphocyte
culture [48,49]. The latter reaction is the in vitro correlate ofthe in vivo graft-versus-
host reaction. Of concern is one recent report in which both graft rejection and
graft-versus-host disease was provoked by blood previously irradiated with 1,500 rads,
suggesting that the lower limit should be raised to 2,000 rads [42]. This change might
be seriously considered for situations in which HLA-identical blood products are being
administered to severely immunosuppressed individuals such as bone marrow trans-
plant recipients.
Clearly, since increasing the dose incurs minimal time and virtually no expense, the
major limitation would be a deleterious effect on the desired transfusion product.
Matureerythrocytes appear to be resistant tolargedosesofirradiation with normal red
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cell survivals and function, even ifthe cells are irradiated after prolonged storage [49].
Prolonged storage after irradiation does result in an increased plasma hemoglobin and
potassium, and a slight increase in red cell adenosine triphosphate and 2,3-
diphosphoglycerate concentrations [49,50]. Thus, red cells should not be stored for
prolonged periods after irradiation. Platelets also seem to be relatively radiation-
resistant, with a normal chromium survival at theusually administered doses, although
one study suggests a diminished initial recovery and diminished correction of the
aspirin defect [49,51,52]. Unlike red cells, five-day storage ofirradiated platelets does
not seem to have an adverse effect [53]. Theresults in granulocyte transfusions seem to
be more variable, with the suggestion that, at the higher ranges of conventional
irradiation doses, some loss of function may be incurred [49,54-56]. It must be
remembered, however, that granulocyte transfusions may be the blood product most
heavily contaminated with lymphocytes. Whether or not these ex vivo defects are
correctable in vivo is unclear. Two theoretical adverse effects need to be considered.
The first is that irradiation might promote increased leaching of plasticizer into the
blood product [49]; todate, nosucheffect has been noted. Second, although circulating
pleuripotential stemcells areextraordinarily sensitive toirradiation and aremost likely
destroyed bythe irradiation, achromosomally damaged, butotherwise intactcell could
engraft, with the subsequent development ofa hematopoietic malignancy.
Morerecently, ultraviolet irradiation hasbeenstudied inthepreventionofalloimmu-
nization by transfusion products [57]. One study demonstrated the abrogation of
transfusion-induced GVHD indogs [58]. Thistechnique is under further investigation,
including methods for the uniform administration ofthe ultraviolet light. The mecha-
nism is unclear but currently is thought to affect both DNA and cell membranes.
Adverse effects have yet to be fully investigated.
SUMMARY
In summary, fatal graft-versus-host disease can be induced when blood products
containing viable lymphocytes are administered to and subsequently engraft in se-
verely immunosuppressed recipients. Many appropriate clinical scenarios have been
described, although this syndrome is probably underdiagnosed and underreported. As
more aggressive therapeutic modalities are developed, the potential for the develop-
ment of this syndrome in treated patients must be carefully considered. Furthermore,
recent descriptions of otherwise immunologically normal patients developing this
syndrome have been noted. In the latter situation, large numbers of lymphocytes
expressing HLA antigens that are not recognized as foreign by the recipient engraft in
the host and recognize foreign host antigents, initiating the GVHD reaction. The
routine use of family-related transfusions should be carefully reconsidered and re-
served for special circumstances. Alternatively, a policy of irradiation of directed
donations can be considered. Since treatment of transfusion-associated GVHD syn-
drome has been unsuccessful, appropriate prophylaxis with ex vivo irradiation ofblood
products will successfully prevent the development of this transfusion complication in
susceptible recipients.
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